Results showed that cancer patients with higher SERTAD1 mRNA expression resulted worse overall survival in brain, colon, lung, blood and ovarian cancer than those with lower SERTAD1 levels (Figure 5 and Figure S1). This evidence concerns the gene SERTAD1 and cancer.